Parker Institute For Cancer Immunotherapy
- Assets
- $255.0m
- Revenue
- $23.7m
- Investments
- $23.3m
- Employees
- 49
- Location
- San Francisco, CA
- Founding
- 06/2015
- Data as of
- 12/2023
- EIN
- 47-3355381
Organization Overview
Parker Institute For Cancer Immunotherapy is located in San Francisco, CA. The organization was established in 2015. According to its NTEE Classification (E12) the organization is classified as: Fund Raising & Fund Distribution, under the broad grouping of Health Care and related organizations. As of 12/2023, Parker Institute For Cancer Immunotherapy employed 49 individuals. This organization is an independent organization and not affiliated with a larger national or regional group of organizations. Parker Institute For Cancer Immunotherapy is a 501(c)(3) and as such, is described as a "Charitable or Religous organization or a private foundation" by the IRS.
For the year ending 12/2023, Parker Institute For Cancer Immunotherapy generated $23.7m in total revenue. This represents a relatively dramatic decline in revenue. Over the past 8 years, the organization has seen revenues fall by an average of (13.2%) each year. All expenses for the organization totaled $42.9m during the year ending 12/2023. As we would expect to see with falling revenues, expenses have declined by (5.8%) per year over the past 8 years. You can explore the organizations financials more deeply in the financial statements section below.
Since 2015, Parker Institute For Cancer Immunotherapy has awarded 110 individual grants totaling $253,300,217. If you would like to learn more about the grant giving history of this organization, scroll down to the grant profile section of this page.
Form
990T
Mission & Program ActivityExcerpts From the 990T Filing
TAX YEAR
2023
Describe the Organization's Mission:
Part 3 - Line 1
SEE SCHEDULE O
Describe the Organization's Program Activity:
PARKER INSTITUTE FOR CANCER IMMUNOTHERAPY (PICI) ENCOURAGES ADVANCES IN CANCER IMMUNOTHERAPY RESEARCH, COLLABORATION, AND DISCOVERY, AND THE TRANSLATION OF THESE ADVANCES INTO CURES AND TREATMENTS FOR THE BENEFIT OF PATIENTS. TO DO THIS, PICI CONDUCTS ITS OWN RESEARCH AND CLINICAL TRIALS AND PROVIDES ITS CONSORTIUM OF PREEMINENT HOSPITALS AND ACADEMIC RESEARCH CENTERS WITH SHARED RESEARCH RESOURCES, SUCH AS SCIENTIFIC EQUIPMENT, CONSUMABLES, BIOINFORMATICS ANALYSIS, AND A SPECIMEN BIOBANK. PICI ALSO FUNDS AND OTHERWISE SUPPORTS CANCER IMMUNOTHERAPY RESEARCH WITHIN ITS CONSORTIUM.
Get More from Intellispect for FreeCreate a free account to get more data, nonprofit salaries, advanced search and more.
Board, Officers & Key Employees
| Name (title) | Role | Hours | Compensation |
|---|---|---|---|
Ute Dugan MD Chief Medical Officer | Officer | 40 | $789,156 |
John Connolly PHD Chief Scientific Officer | Officer | 40 | $763,765 |
Kevin Marks Chief Legal Officer | 40 | $559,373 | |
Tarak Mody Chief Business Officer | 40 | $614,960 | |
Shane Corcoran Senior Vp, Strat. Ops. & Comms | 40 | $547,440 | |
Sara Coblin Sr VP Finance & Admin. | Officer | 40 | $548,044 |
Outside Vendors & Contractors
| Vendor Name (Service) | Service Year | Compensation |
|---|---|---|
The Trustees Of The Univ Of Pa Test/validation Exp. | 12/30/23 | $633,217 |
Luma Bridge Clinical Trial Exp | 12/30/23 | $2,402,357 |
Regents Of Univ Of Cal San Franc Patent/clinic Exp. | 12/30/23 | $723,631 |
Clinverse-clinpay Clinical Trial Exp | 12/30/23 | $599,732 |
The Regents Of The Univ Of Califor Patent Expenses | 12/30/23 | $544,364 |
Financial Statements
| Statement of Revenue | |
|---|---|
| Federated campaigns | $0 |
| Membership dues | $0 |
| Fundraising events | $0 |
| Related organizations | $0 |
| Government grants | $0 |
| All other contributions, gifts, grants, and similar amounts not included above | $1,204,708 |
| Noncash contributions included in lines 1a–1f | $0 |
| Total Revenue from Contributions, Gifts, Grants & Similar | $1,204,708 |
| Total Program Service Revenue | $8,658,418 |
| Investment income | $5,346,695 |
| Tax Exempt Bond Proceeds | $0 |
| Royalties | $1,451,074 |
| Net Rental Income | $0 |
| Net Gain/Loss on Asset Sales | $7,001,741 |
| Net Income from Fundraising Events | $0 |
| Net Income from Gaming Activities | $0 |
| Net Income from Sales of Inventory | $0 |
| Miscellaneous Revenue | $0 |
| Total Revenue | $23,662,636 |
| Statement of Expenses | |
|---|---|
| Grants and other assistance to domestic organizations and domestic governments. | $14,807,382 |
| Grants and other assistance to domestic individuals. | $0 |
| Grants and other assistance to Foreign Orgs/Individuals | $0 |
| Benefits paid to or for members | $0 |
| Compensation of current officers, directors, key employees. | $2,248,427 |
| Compensation of current officers, directors, key employees. | $586,690 |
| Compensation to disqualified persons | $0 |
| Other salaries and wages | $7,587,904 |
| Pension plan accruals and contributions | $139,902 |
| Other employee benefits | $580,620 |
| Payroll taxes | $511,446 |
| Fees for services: Management | $0 |
| Fees for services: Legal | $2,050,912 |
| Fees for services: Accounting | $396,281 |
| Fees for services: Lobbying | $0 |
| Fees for services: Fundraising | $0 |
| Fees for services: Investment Management | $0 |
| Fees for services: Other | $1,670,313 |
| Advertising and promotion | $41,452 |
| Office expenses | $134,831 |
| Information technology | $1,068,568 |
| Royalties | $0 |
| Occupancy | $1,505,114 |
| Travel | $783,088 |
| Payments of travel or entertainment expenses for any federal, state, or local public officials | $0 |
| Conferences, conventions, and meetings | $2,997,816 |
| Interest | $0 |
| Payments to affiliates | $0 |
| Depreciation, depletion, and amortization | $409,412 |
| Insurance | $214,185 |
| All other expenses | $218,416 |
| Total functional expenses | $42,903,351 |
| Balance Sheet | |
|---|---|
| Cash—non-interest-bearing | $3,286,878 |
| Savings and temporary cash investments | $65,585,234 |
| Pledges and grants receivable | $0 |
| Accounts receivable, net | $4,756,494 |
| Loans from Officers, Directors, or Controlling Persons | $764,842 |
| Loans from Disqualified Persons | $0 |
| Notes and loans receivable | $0 |
| Inventories for sale or use | $0 |
| Prepaid expenses and deferred charges | $2,651,610 |
| Net Land, buildings, and equipment | $255,000 |
| Investments—publicly traded securities | $0 |
| Investments—other securities | $23,331,587 |
| Investments—program-related | $151,742,635 |
| Intangible assets | $0 |
| Other assets | $2,653,463 |
| Total assets | $255,027,743 |
| Accounts payable and accrued expenses | $7,199,228 |
| Grants payable | $0 |
| Deferred revenue | $875,000 |
| Tax-exempt bond liabilities | $0 |
| Escrow or custodial account liability | $0 |
| Loans and other payables to any current Officer, Director, or Controlling Person | $7,000,000 |
| Secured mortgages and notes payable | $0 |
| Unsecured mortgages and notes payable | $0 |
| Other liabilities | $37,739,542 |
| Total liabilities | $52,813,770 |
| Net assets without donor restrictions | $194,119,787 |
| Net assets with donor restrictions | $8,094,186 |
| Capital stock or trust principal, or current funds | $0 |
| Paid-in or capital surplus, or land, building, or equipment fund | $0 |
| Retained earnings, endowment, accumulated income, or other funds | $0 |
| Total liabilities and net assets/fund balances | $255,027,743 |
Grants Awarded
Over the last fiscal year, Parker Institute For Cancer Immunotherapy has awarded $13,967,003 in support to 12 organizations.
| Grant Recipient | Amount |
|---|---|
BECKMAN RESEARCH INSTITUTE OF CITY OF HOPE PURPOSE: SUPPORT RESEARCH IN FIELD OF CANCER IMMUNOTHERAPY | $333,333 |
CHILDREN'S HOSPITAL OF PHILADELPHIA PURPOSE: SUPPORT RESEARCH IN FIELD OF CANCER IMMUNOTHERAPY | $360,000 |
FHCRC - HUTCHINSON PURPOSE: SUPPORT RESEARCH IN FIELD OF CANCER IMMUNOTHERAPY | $528,249 |
ICAHN SCHOOL OF MEDICINE PURPOSE: SUPPORT RESEARCH IN FIELD OF CANCER IMMUNOTHERAPY | $203,737 |
MEMORIAL SLOAN KETTERING CANCER CENTER PURPOSE: SUPPORT RESEARCH IN FIELD OF CANCER IMMUNOTHERAPY | $278,726 |
STANFORD UNIVERSITY PURPOSE: SUPPORT RESEARCH IN FIELD OF CANCER IMMUNOTHERAPY | $2,947,554 |